免疫系统
抗原
免疫学
医学
接种疫苗
血小板活化
血小板因子4
血小板
作者
Diana F. Cedillo‐Alcantar,Adam J. Kanack,Seonhwa Lee,Alan M. Gonzalez‐Suarez,Kihak Gwon,Emily Mauch,Thi Thanh‐Qui Nguyen,Anand Padmanabhan,Alexander Revzin
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2025-05-16
标识
DOI:10.1101/2025.05.15.25327633
摘要
ABSTRACT Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a new disorder that emerged in the wake of COVID-19 vaccination. It is a rare but life-threating condition that requires aggressive course of treatment to improve patient outcomes. To date, there has not been an effective diagnostic assay for detecting VITT. Instead, definitive diagnosis requires satisfying several criteria including history of recent vaccination, platelet count, positive ELISA result for a closely related thrombotic disorder, heparin-induced thrombocytopenia (HIT) and PF4-dependent functional assays. Our study describes a technically simple antigenic assay for direct diagnosis of autoimmune antibodies (Abs) associated with VITT. We first show that cross-linked platelet factor 4 (PF4) represents an antigenic target specific for VITT Abs. We then incorporate this antigenic target into a microfluidic electrochemical biosensor and demonstrate specific and sensitive detection of VITT Abs in a fully automated manner while using microliter volumes of patient sera. We tested 51 patient samples using the microfluidic electrochemical biosensor and demonstrated 100% sensitivity and specificity for VITT sera compared to healthy controls and HIT patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI